Pemetrexed Accord 100 mg powder for concentrate for solution for infusion.
Sponsors
Incyte Corp., Summit Therapeutics Inc., Genmab A/S, Universitair Ziekenhuis Gent
Conditions
Malignant solid tumors: endometrial carcinoma (EC)Metastatic nonsquamous or squamous non-small cell lung cancerPatients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatmentmetastatic non-small-cell lung canceror cervical cancer.squamous cell carcinoma of the head and neck (SCCHN)triple-negative breast cancer (TNBC)urothelial carcinoma (UC)
Phase 1
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
Active, not recruitingCTIS2023-509059-15-00
Start: 2019-04-30Target: 295Updated: 2026-01-16
A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metastatic non-small-cell lung cancer (DARE-LUNG)
Not yet recruitingCTIS2025-521577-13-00
Target: 64Updated: 2025-09-11
Phase 3
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)
Active, not recruitingCTIS2023-504434-22-00
Start: 2023-10-03Target: 45Updated: 2025-12-16
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)
Active, not recruitingCTIS2022-501987-16-00
Start: 2020-10-02Target: 14Updated: 2025-08-05